Micromedic Reports Successful Clinical Study Results for Monitoring Bladder Cancer Recurrence
Micromedic Technologies announced the results of a blinded, multi-center clinical study using the CellDetect® non-invasive technology to detect bladder cancer recurrence in patients with a history of the disease. The study was conducted in nine medical centers and reported the results on urine samples from 217 patients.
CellDetect® successfully identified cancerous cells with 84.4% sensitivity and 82.7% specificity. In addition to its high sensitivity for advanced stage tumors and high-grade malignancy, the test was also found to exhibit high sensitivity for early stage tumors and low-grade malignancies.